Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Articolo
Data di Pubblicazione:
2022
Abstract:
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Advanced HCC; Atezolizumab; Bevacizumab; First line; Systemic treatment; Albumins; Antibodies, Monoclonal, Humanized; Bevacizumab; Bilirubin; Female; Humans; Male; Sorafenib; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Liver Neoplasms; Venous Thrombosis
Elenco autori:
Fulgenzi, Claudia Angela Maria; Cheon, Jaekyung; D'Alessio, Antonio; Nishida, Naoshi; Ang, Celina; Marron, Thomas U; Wu, Linda; Saeed, Anwaar; Wietharn, Brooke; Cammarota, Antonella; Pressiani, Tiziana; Personeni, Nicola; Pinter, Matthias; Scheiner, Bernhard; Balcar, Lorenz; Napolitano, Andrea; Huang, Yi-Hsiang; Phen, Samuel; Naqash, Abdul Rafeh; Vivaldi, Caterina; Salani, Francesca; Masi, Gianluca; Bettinger, Dominik; Vogel, Arndt; Schönlein, Martin; von Felden, Johann; Schulze, Kornelius; Wege, Henning; Galle, Peter R; Kudo, Masatoshi; Rimassa, Lorenza; Singal, Amit G; Sharma, Rohini; Cortellini, Alessio; Gaillard, Vincent E; Chon, Hong Jae; Pinato, David James
Link alla scheda completa:
Pubblicato in: